Haisco Pharmaceuticals (Meishan) Co., Ltd. is a wholly owned subsidiary of Haisco Pharmaceutical Group Co., Ltd., established in 2013. It covers an area of 180 mu, and has more than 4,000 m2 of workshops and laboratories that meet GMP standards, it has nearly 400 employees currently and a cumulative investment of 400 million yuan. It is a comprehensive pharmaceutical manufacture enterprise which integrates the scaling commercial production, process development optimization and quality research.

As the commercial production base of non-sterile drug substance and solid formulations of the Group, the company has several production lines for such as tablets, capsules, granules, ointments, creams and drug substances, with more than 30 marketed varieties currently and more than 20 projects under development, which are widely involved in the fields of cardiovascular, anti-infection, digestive system, mental system, liver disease and diabetes mellitus. Since 2016, our company has experienced more than ten registered site inspections and GMP certification inspections for dozens of projects, including: site inspection of drug registration, site inspection of generic drug consistency evaluation, etc.

The company is committed to providing the most up-to-date and high-quality drugs for the majority of patients, actively fulfilling social responsibilities and becoming a first-class pharmaceutical production base that meets cGMP standards, occupational health and safety management system and environmental management system in China.

The company passed the certification as Work Safety Standardization Grade II Enterprise (hazardous chemicals) in 2018 and was listed as a provincial safety culture construction demonstration enterprise in Sichuan Province in 2019.